Viking Therapeutics Inc

Healthcare · Biotechnology

29.90$ -1.9% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Viking Therapeutics Inc (VKTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 522 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet VKTX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	16	15	15	14	12	22	79	144	307	302	300	294	290	284	277	271	264	257	250	238	224	211	195	182	167	169	151	401	383	368	968	947	938	908	867	828	739	716	608	522
Current Assets	16	14	15	14	12	22	79	144	307	302	299	294	289	284	276	271	263	256	250	238	224	211	193	180	165	167	149	399	381	367	966	946	937	907	866	827	739	716	608	518
Cash	3.1	3.1	4.4	3.4	2.6	9.0	36	35	170	25	14	19	31	8.4	15	19	3.9	29	17	8.8	11	26	12	16	29	37	18	70	37	56	196	44	50	27	38	34	100	166	118	126
Cash & Short-Term Investments	15	13	12	12	9.8	21	77	142	304	302	299	293	288	276	269	263	255	248	242	228	216	202	185	169	155	155	136	393	376	362	963	942	930	903	852	808	715	706	603	502
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	0.8	0.7	0.7	0.6	0.5	0.5	0.4	0.3	0.2	0.2	0.1	0.0	1.6	1.6	1.5	1.4	1.3	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	6.1	6.5	7.6	7.7	9.6	8.7	6.3	4.1	4.7	4.6	5.5	6.1	6.6	7.1	8.8	9.3	9.8	12	13	13	11	8.8	13	16	15	23	17	15	14	20	34	26	26	28	20	32	26	77	106	114
Current Liabilities	6.1	6.5	3.4	7.7	9.6	8.7	6.3	4.1	4.7	4.6	4.9	5.6	6.2	6.8	8.5	9.1	9.7	12	13	13	11	8.8	11	15	14	22	16	13	13	19	33	25	26	27	20	32	26	77	106	110
Short-Term Debt	2.8	3.3	3.3	3.1	3.2	3.5	3.7	–	–	–	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.1	0.0	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.5	0.5	0.5	0.5	0.4	0.1	–	0.2
Accounts Payable	0.9	1.2	1.7	1.3	1.6	1.5	0.7	1.5	1.2	1.0	1.7	1.9	2.1	2.4	3.1	3.2	2.8	4.0	4.8	4.2	2.9	1.4	3.1	6.1	3.1	8.5	3.8	5.6	5.7	7.5	5.2	11	0.3	9.8	7.7	5.5	4.4	53	67	69
Long-Term Debt	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	–	0.6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	10	8.0	7.5	6.6	2.2	13	73	140	302	298	295	288	283	277	268	262	254	244	237	225	213	202	182	165	151	145	134	386	368	348	934	921	911	880	847	795	713	639	502	408
Retained Earnings	-57	-60	-65	-71	-77	-81	-84	-91	-98	-103	-108	-116	-121	-129	-138	-148	-157	-168	-182	-198	-211	-223	-239	-257	-272	-292	-312	-331	-353	-378	-405	-428	-452	-488	-534	-599	-690	-848	-1,006	-1,134
Shares Outstanding	19	20	22	24	27	30	45	53	61	71	72	72	72	72	72	72	73	73	75	78	78	77	77	77	77	77	78	99	100	100	103	110	111	111	112	112	112	114	116	116

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings